Received by email:

File: AB E PR Option grant Oct 24 2014.doc

 
PRESS RELEASE                                    
FOR IMMEDIATE DISTRIBUTION 
October 24, 2014

ARCH BIOPARTNERS GRANTS STOCK OPTIONS

Toronto, ON - October 24, 2014 - Arch Biopartners Inc ("Arch" or the "Company")(CNSX-ACH and OTC: FOIFF) announced tod
--->ay that the Company has granted 1,200,000 incentive stock options to certain of its directors, officers and consultant
--->s pursuant to its 2014 stock option plan. Each stock option is exercisable into a common share of the company for a pe
--->riod of five years. A total of 900,000 options are exercisable at $0.30 per share; 100,000 are exercisable at $0.40 pe
--->r share and 200,000 are exercisable at $0.50 per share. 

The Company currently has 50,975,179 common shares outstanding.

About Arch Biopartners 
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology to meet
---> unmet medical or industrial needs. The Company's lead technology is called MetaMxTM, which targets brain tumor initia
--->ting cells in order to develop new imaging, diagnostic and therapeutic treatments for malignant glioma. 

For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com. 
The Company's website address is: www.archbiopartners.com . 
Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements that inv
--->olve various risks and uncertainties, including, without limitation, statements regarding the future plans and objecti
--->ves of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and futur
--->e events could differ materially from those anticipated in such statements. These and all subsequent written and oral 
--->forward-looking statements are based on the estimates and opinions of management on the dates they are made and are ex
--->pressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statem
--->ents should circumstances or management's estimates or opinions change. 
 The CNSX has not reviewed and does not accept responsibility for the adequacy of this
release. 
For more information, please contact:  
(647) 428 7031 
info@archbiopartners.com